EBS
Emergent BioSolutions Inc.
$9.13
+$0.68(+8.05%)
58
Overall
80
Value
54
Tech
42
Quality
Market Cap
$537.80M
Volume
1.08M
52W Range
$5.31 - $14.06
Target Price
$12.00
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $488.8M | $560.9M | $782.4M | $1.1B | $1.3B | $1.5B | $1.1B | $1.0B | $1.0B | $742.9M | ||
| Total Revenue | $296.3M | $560.9M | $782.4M | $1.1B | $1.6B | $1.8B | $1.1B | $1.0B | $1.0B | $742.9M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-131.3M | $-187.7M | $-322.3M | $433.5M | $537.0M | $748.1M | $693.1M | $705.4M | $681.3M | $326.2M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $357.5M | $373.2M | $460.1M | $672.5M | $925.2M | $891.3M | $383.0M | $1.0B | $362.3M | $416.7M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-383.3M | $-436.6M | $-692.6M | $991.9M | $1.1B | $1.4B | $546.3M | $1.8B | $1.2B | $642.8M | ||
| Research & Development | $108.3M | $97.4M | $142.8M | $226.2M | $234.5M | $234.0M | $188.3M | $111.4M | $70.7M | $53.2M | ||
| Research Expense | $108.3M | $97.4M | $142.8M | $226.2M | $234.5M | $234.0M | $188.3M | $111.4M | $70.7M | $53.2M | ||
| Selling, General & Administrative | $143.7M | $142.9M | $202.5M | $273.5M | $303.3M | $348.4M | $339.5M | $368.4M | $308.0M | $186.1M | ||
| Selling & Marketing Expenses | $143.7M | $142.9M | $202.5M | -- | -- | -- | -- | $26.9M | $23.0M | -- | ||
| General & Administrative Expenses | $-1.4M | $-1.6M | $-3.3M | $273.5M | $303.3M | $348.4M | $339.5M | $368.4M | $308.0M | $186.1M | ||
| Salaries & Wages | $-18.5M | $-15.2M | $-23.2M | $1.7M | $2.4M | $2.0M | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-28.0M | $8.6M | $25.0M | $58.7M | $59.8M | $58.5M | $59.9M | $65.6M | $65.1M | $65.1M | ||
| Depreciation & Amortization | $-28.0M | $8.6M | $25.0M | $58.7M | $59.8M | $58.5M | $59.9M | $65.6M | $65.1M | $65.1M | ||
| Amortization | $-7.7M | $8.6M | $25.0M | $58.7M | $59.8M | $58.5M | $59.9M | $65.6M | $65.1M | $65.1M | ||
| Other Operating Expenses | $-299.0K | $-500.0K | $-300.0K | $-1.5M | $-600.0K | $-4.6M | -- | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $105.5M | $124.3M | $89.8M | $114.1M | $433.8M | $352.6M | $-170.0M | $-726.4M | $-108.7M | $100.1M | ||
| EBITDA | $136.8M | $160.8M | $154.5M | $229.5M | $557.7M | $461.5M | $-34.3M | $-496.9M | $44.3M | $247.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $7.6M | $6.6M | $9.9M | $38.4M | $31.3M | $34.5M | $37.3M | $87.9M | $71.0M | $59.3M | ||
| Interest Income Operating | $3.3M | $2.6M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Intinc | $1.1M | $1.8M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-6.6M | $-6.6M | $-9.9M | $-38.4M | $-31.3M | $-34.5M | $-37.3M | $-800.0K | $-71.0M | $-59.3M | ||
| Other Income/Expense | $-263.0K | $-900.0K | $-1.6M | $-1.7M | $-288.5M | $-296.0M | $-18.4M | $223.6M | $-9.6M | $-29.8M | ||
| Other Special Charges | $263.0K | $900.0K | $1.6M | $1.7M | $288.5M | $296.0M | $-11.7M | $8.9M | $12.5M | $42.0M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | $-12.3M | $-27.7M | -- | -- | -- | -- | $29.3M | $22.5M | -- | ||
| Special Income Charges | -- | $12.3M | $27.7M | -- | -- | $-41.7M | $-6.7M | $-218.2M | $-22.5M | -- | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | $41.7M | $6.7M | $218.2M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $98.5M | $118.2M | $91.4M | $115.8M | $443.2M | $337.7M | $-181.7M | $-643.3M | $-71.9M | $142.1M | ||
| Pre-Tax Income | $99.2M | $118.6M | $81.5M | $77.4M | $407.2M | $314.4M | $-219.0M | $-731.2M | $-142.9M | $82.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $36.7M | $36.0M | $18.8M | $22.9M | $106.1M | $83.7M | $-7.4M | $29.3M | $47.7M | $30.2M | ||
| NET INCOME | ||||||||||||
| Net Income | $51.8M | $82.6M | $62.7M | $54.5M | $305.8M | $219.5M | $-211.6M | $-760.5M | $-190.6M | $52.6M | ||
| Net Income (Continuing Operations) | $51.8M | $82.6M | $62.7M | $54.5M | $305.1M | $230.9M | $-211.6M | $-760.5M | $-190.6M | $52.6M | ||
| Net Income (Discontinued Operations) | $51.8M | $82.6M | $62.7M | $54.5M | $305.8M | $219.5M | $-211.6M | $-760.5M | $-190.6M | $52.6M | ||
| Net Income (Common Stockholders) | $51.8M | $82.6M | $62.7M | $54.5M | $305.8M | $219.5M | $-211.6M | $-760.5M | $-190.6M | $52.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $94.2M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-514.6M | $-624.3M | $-1.0B | $1.4B | $1.5B | $2.2B | $1.2B | $1.8B | $1.8B | $969.0M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $40.2M | $41.8M | $50.1M | $51.5M | $52.7M | $53.5M | $50.1M | $51.2M | $53.0M | $53.5M | ||
| Average Shares Outstanding (Diluted) | $49.3M | $50.3M | $51.4M | $52.4M | $53.8M | $54.1M | $50.1M | $51.2M | $53.0M | $56.7M | ||
| Shares Outstanding | $40.7M | $49.5M | $51.2M | $52.0M | $53.3M | $50.5M | $50.1M | $52.2M | $54.3M | $51.8M | ||
| Basic EPS | $1.29 | $1.98 | $1.25 | $1.06 | $5.79 | $4.32 | $-4.47 | $-14.85 | $-3.6 | $0.98 | ||
| Basic EPS (Continuing Operations) | $1.56 | $1.98 | $1.25 | $1.06 | $5.79 | $4.32 | $-4.47 | $-14.85 | $-3.6 | $0.98 | ||
| Diluted EPS | $1.13 | $1.71 | $1.22 | $1.04 | $5.67 | $4.27 | $-4.47 | $-14.85 | $-3.6 | $0.93 | ||
| Diluted EPS (Continuing Operations) | $1.35 | $1.71 | $1.22 | $1.04 | $5.67 | $4.27 | $-4.47 | $-14.85 | $-3.6 | $0.93 | ||
| OTHER METRICS | ||||||||||||
| Basic Discontinuous Operations | $-0.27 | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Diluted Discontinuous Operations | $-0.22 | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of Business | -- | -- | -- | -- | -- | -- | -- | $74.2M | $24.3M | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | $-10.7M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Interest Expense Operating | $-8.3M | $-7.0M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Minority Interests | $99.2M | $118.6M | $81.5M | -- | -- | -- | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | $-10.7M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $-1.4M | $-1.6M | $-3.3M | $273.5M | $303.3M | $348.4M | $339.5M | $368.4M | $308.0M | $186.1M | ||
| Other Impairment Of Capital Assets | $-5.6M | -- | -- | -- | $29.0M | $41.7M | -- | $306.7M | $27.2M | $12.2M | ||
| Rent And Landing Fees | $-1.4M | $-1.6M | $-3.3M | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $143.7M | $142.9M | $202.5M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | $-12.3M | $-27.7M | -- | -- | -- | -- | $29.3M | $22.5M | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EBS | $9.13 | +8.0% | 1.08M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Emergent BioSolutions Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW